IL23 is a central cytokine in the differentiation and maintenance of Th17-driven inflammatory responses.
Mechanistic studies strongly support the IL23/IL17 axis as a driver of psoriatic inflammation and tissue pathology.
Pathway-selective inhibition is biologically coherent and well supported by disease immunology.
Φ layer — Genetic evidence
Status: STRONG / SUPPORTIVE
Human genetics support the relevance of the IL23 pathway in immune-mediated disease.
Variants affecting IL23-related signaling components, including IL23R, reinforce the causal importance of this axis in inflammatory pathology.
Genetic evidence supports both pathway relevance and therapeutic prioritization.
Σ layer — Clinical evidence
Status: STRONG
Clinical inhibition of IL23 has produced strong and durable efficacy in psoriasis.
Therapeutic outcomes validated the pathway as a highly actionable inflammatory target and supported selective immune modulation as a viable drug discovery strategy.
Clinical evidence confirms robust translational success.
IL23 represents a high-confidence target in which mechanistic immunology, human pathway relevance, and clinical intervention align strongly.
Cross-layer evidence alignment indicates low translational risk and strong decision confidence for pathway-directed therapy.
Why this case matters
IL23 is important because it shows that successful target validation does not always require broad pathway suppression.
Selective immune modulation can outperform less discriminating approaches when mechanistic logic and disease context are well aligned.